Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 660848
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BI 660848 is a small molecule drug initially developed by C.H. Boehringer Sohn AG & Co. KG, now part of Boehringer Ingelheim GmbH. It was investigated for its potential therapeutic effects, particularly in treating nervous system diseases, including neuropathic pain. However, its development has been discontinued.
02
Targets
TRPC4 (Transient receptor potential cation channel subfamily C member 4)TRPC5 (Transient receptor potential Canonical-5)SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on BI 660848.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 660848.